» Articles » PMID: 26604941

Rare Causes of Osteoporosis

Overview
Date 2015 Nov 26
PMID 26604941
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is a metabolic bone disease characterized by loss of bone mass and strength, resulting in increased risk of fractures. It is classically divided into primary (post-menopausal or senile), secondary and idiopathic forms. There are many rare diseases, that cause directly or indirectly osteoporosis. The identification and classification of most of these rare causes of osteoporosis is crucial for the specialists in endocrinology and not, in order to prevent this bone complication and to provide for an early therapy. Several pathogenic mechanisms are involved, including various aspects of bone metabolism such as: decreased bone formation, increased bone resorption, altered calcium, phosphorus and/or vitamin D homeostasis, and abnormal collagen synthesis. In this review, less common forms of primary and secondary osteoporosis are described, specifying, if applicable: genetic causes, epidemiology, clinical features, and pathogenic mechanisms causing osteoporosis. A greater awareness of all rare causes of osteoporosis could reduce the number of cases classified as idiopathic osteoporosis and allow the introduction of appropriate and timely treatments.

Citing Articles

Alendronate for Effective Treatment of Male Osteoporosis: An Insight.

Al Lawati H, Al Busaidi S, Al Rawahi T, Al Lawati A, Kifah A, Das S Curr Pharm Des. 2024; 31(1):26-36.

PMID: 39238374 DOI: 10.2174/0113816128310838240820065324.


Prevalence of osteoporosis and associated factors among people aged 50 years and older in the Madhesh province of Nepal: a community-based cross-sectional study.

Chaudhary N, Sunuwar D, Sapkota M, Pant S, Pradhan M, Bhandari K J Health Popul Nutr. 2024; 43(1):100.

PMID: 38965638 PMC: 11225282. DOI: 10.1186/s41043-024-00591-7.


Bone mineral density parameters and related nutritional factors in vegans, lacto-ovo-vegetarians, and omnivores: a cross-sectional study.

Galchenko A, Rizzo G, Sidorova E, Skliar E, Baroni L, Visaggi P Front Nutr. 2024; 11:1390773.

PMID: 38919395 PMC: 11196821. DOI: 10.3389/fnut.2024.1390773.


Role of miRNA-regulated type H vessel formation in osteoporosis.

Zhang D, Wang Y, Zhou Z, Wang L, Liu C, Jiang Y Front Endocrinol (Lausanne). 2024; 15:1394785.

PMID: 38883597 PMC: 11176424. DOI: 10.3389/fendo.2024.1394785.


Sophoraflavanone G Inhibits RANKL-Induced Osteoclastogenesis via MAPK/NF-κB Signaling Pathway.

Li X, Deng W, Tang K, Zhang S, Liang Z, Liu W Mol Biotechnol. 2024; .

PMID: 38780825 DOI: 10.1007/s12033-024-01185-8.


References
1.
Panis B, Forget P, van Kroonenburgh M, Vermeer C, Menheere P, Nieman F . Bone metabolism in galactosemia. Bone. 2004; 35(4):982-7. DOI: 10.1016/j.bone.2004.06.004. View

2.
Paccou J, Fardellone P, Cortet B . Cystic fibrosis-related bone disease. Curr Opin Pulm Med. 2013; 19(6):681-6. DOI: 10.1097/MCP.0b013e3283659e35. View

3.
Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T . Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis. Adv Med Sci. 2013; 58(2):338-43. DOI: 10.2478/ams-2013-0011. View

4.
OSullivan S, Grey A, Singh R, Reid I . Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006; 17(7):1008-12. DOI: 10.1007/s00198-006-0112-3. View

5.
Barvencik F, Beil F, Gebauer M, Busse B, Koehne T, Seitz S . Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis. Osteoporos Int. 2011; 22(10):2667-75. DOI: 10.1007/s00198-011-1528-y. View